FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3095043345> ?p ?o ?g. }

• W3095043345 endingPage "40" @default.
• W3095043345 startingPage "39" @default.
• W3095043345 abstract "Introduction: Venetoclax (VEN) is an oral BCL2 inhibitor, that has been shown to overcome apoptotic stress in cells from patients (pts) with high-risk myelodysplastic syndrome (MDS). Pre-clinical evidence indicates that VEN plus azacytidine (Aza) combination results in synergistic effects in myeloid malignancies. The objective of this trial is to evaluate the safety, tolerability, and overall response rate (ORR) of VEN in combination with Aza in pts with treatment-naive high-risk MDS or chronic myelomonocytic leukemia (CMML) and pts that were relapsed/refractory (R/R) to prior hypomethylating agent (HMA) therapy. Methods: This is a single-arm phase I/II clinical trial for pts with treatment-naive high-risk MDS or CMML, or pts with R/R MDS or CMML post-HMA failure (NCT04160052). Pts with prior BCL2 inhibitor therapy or low-risk disease (IPSS low or Int-1) are excluded. Aza is administered at 75mg/m2 IV or SC for 5 days on days 1-5 of each treatment cycle. VEN is studied at 100 mg, 200 mg, or 400 mg daily, on days 1-7 or 1-14 of each cycle. The primary endpoint is to determine the maximum tolerated dose and dose-limiting toxicity (DLT) of VEN in combination with Aza, as well as to evaluate ORR, defined as achieving complete remission (CR), marrow complete remission (mCR), partial response (PR), or hematologic improvement (HI) lasting ≥4 weeks. Response is assessed based on the modified International Working Group 2006 criteria (Cheson et al Blood 2006). Overall survival (OS) is calculated from the start date of treatment to the date of death, or last follow-up. Progression-free survival (PFS) is calculated from the start date of treatment to the date of disease progression, or last follow-up. Duration of response is calculated from the date of response to the date of disease progression, or last follow-up. Safety profile events were recorded according to the CTCAE v5.0. Results: To date 9 pts were enrolled. Four pts received VEN at 100mg dose, 3 pts at 200mg dose, and 2 pts at 400mg dose on days 1-7. There has been no protocol defined DLTs. The median age was 66 years (range, 59-83), 89% were male, 67% with MDS, 67% with normal karyotype. Five pts (56%) were treatment-naive, and 4 (44%) with R/R disease. Of the treatment-naive cohort (N=5), 4/5 (80%) pts had normal karyotype and none had TP53 mutations. ORR rate in this treatment-naive cohort was 100%, all pts achieving mCR, of which 1 (20%) had neutrophil response. Of the R/R cohort (N=4), cytogenetics were normal in 2/4 (50%) and complex in 2/4 (50%), and 2/4 (50%) had TP53 mutations. ORR in this R/R cohort was 3/4 (75%), all achieving mCR. One pt (25%) had stable disease (Table 1 and Figure 1). With a median follow-up duration of 3.6 months (95% CI: 1.4-8.4), 3 (33%) had disease progression and 1 (11%) died. Pts received median 2 courses of therapy (range, 1-4). One pt went to transplant. Median progression-free survival (PFS) for the entire cohort was 4.6 months (95% CI: 3.4-NA) and median OS has not been reached (Figure 2). Median duration of response is 4.1 months (95% CI: 2.4-NA). Possibly/probably related grade 3/4 adverse events included neutropenia in 4/9 (44%), thrombocytopenia in 3/9 (33%), and anemia in 1/9 (11%) pts. There were no grade 5 events (Table 2). Conclusions: The administration of VEN with Aza appears safe and well tolerated in treatment-naive and R/R pts with high-risk MDS and CMML. The study continues to accrue. Disclosures Thompson: Adaptive Biotechnologies: Consultancy, Research Funding; AbbVie: Research Funding; Pharmacyclics: Research Funding; Genentech: Consultancy; Janssen-Cilag: Honoraria. Alvarado:BerGenBio ASA: Research Funding; FibroGen: Research Funding; Sun Pharma: Research Funding; Daiichi-Sankyo: Research Funding; Tolero Pharmaceuticals: Research Funding; MEI Pharma: Research Funding; Astex Pharmaceuticals: Research Funding; Jazz Pharmaceuticals: Research Funding. Jabbour:Genentech: Other: Advisory role, Research Funding; AbbVie: Other: Advisory role, Research Funding; Adaptive Biotechnologies: Other: Advisory role, Research Funding; BMS: Other: Advisory role, Research Funding; Takeda: Other: Advisory role, Research Funding; Amgen: Other: Advisory role, Research Funding; Pfizer: Other: Advisory role, Research Funding. Kantarjian:BioAscend: Honoraria; Delta Fly: Honoraria; Abbvie: Honoraria, Research Funding; Daiichi-Sankyo: Honoraria, Research Funding; Janssen: Honoraria; Oxford Biomedical: Honoraria; Aptitute Health: Honoraria; Adaptive biotechnologies: Honoraria; Actinium: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Research Funding; Pfizer: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Jazz: Research Funding; Immunogen: Research Funding; Amgen: Honoraria, Research Funding; BMS: Research Funding; Ascentage: Research Funding. Garcia-Manero:Amphivena Therapeutics: Research Funding; Bristol-Myers Squibb: Consultancy, Research Funding; Acceleron Pharmaceuticals: Consultancy, Honoraria; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astex Pharmaceuticals: Consultancy, Honoraria, Research Funding; Helsinn Therapeutics: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; AbbVie: Honoraria, Research Funding; H3 Biomedicine: Research Funding; Merck: Research Funding; Novartis: Research Funding; Jazz Pharmaceuticals: Consultancy; Onconova: Research Funding." @default.
• W3095043345 created "2020-11-09" @default.
• W3095043345 creator A5027786056 @default.
• W3095043345 creator A5046517633 @default.
• W3095043345 creator A5049385583 @default.
• W3095043345 creator A5051949215 @default.
• W3095043345 creator A5061026876 @default.
• W3095043345 creator A5070065917 @default.
• W3095043345 creator A5080883357 @default.
• W3095043345 creator A5083793750 @default.
• W3095043345 creator A5090435894 @default.
• W3095043345 date "2020-11-05" @default.
• W3095043345 modified "2023-10-15" @default.
• W3095043345 title "Initial Results of a Phase I/II Study of Venetoclax in Combination with Azacitidine in Treatment-Naive and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)" @default.
• W3095043345 doi "https://doi.org/10.1182/blood-2020-140644" @default.
• W3095043345 hasPublicationYear "2020" @default.
• W3095043345 type Work @default.
• W3095043345 sameAs 3095043345 @default.
• W3095043345 citedByCount "3" @default.
• W3095043345 countsByYear W30950433452021 @default.
• W3095043345 countsByYear W30950433452023 @default.
• W3095043345 crossrefType "journal-article" @default.
• W3095043345 hasAuthorship W3095043345A5027786056 @default.
• W3095043345 hasAuthorship W3095043345A5046517633 @default.
• W3095043345 hasAuthorship W3095043345A5049385583 @default.
• W3095043345 hasAuthorship W3095043345A5051949215 @default.
• W3095043345 hasAuthorship W3095043345A5061026876 @default.
• W3095043345 hasAuthorship W3095043345A5070065917 @default.
• W3095043345 hasAuthorship W3095043345A5080883357 @default.
• W3095043345 hasAuthorship W3095043345A5083793750 @default.
• W3095043345 hasAuthorship W3095043345A5090435894 @default.
• W3095043345 hasBestOaLocation W30950433451 @default.
• W3095043345 hasConcept C104317684 @default.
• W3095043345 hasConcept C121332964 @default.
• W3095043345 hasConcept C126322002 @default.
• W3095043345 hasConcept C142424586 @default.
• W3095043345 hasConcept C143998085 @default.
• W3095043345 hasConcept C150194340 @default.
• W3095043345 hasConcept C185592680 @default.
• W3095043345 hasConcept C190727270 @default.
• W3095043345 hasConcept C197934379 @default.
• W3095043345 hasConcept C203092338 @default.
• W3095043345 hasConcept C2776063141 @default.
• W3095043345 hasConcept C2776239401 @default.
• W3095043345 hasConcept C2776364478 @default.
• W3095043345 hasConcept C2776694085 @default.
• W3095043345 hasConcept C2777063308 @default.
• W3095043345 hasConcept C2777928532 @default.
• W3095043345 hasConcept C2777938653 @default.
• W3095043345 hasConcept C2778375690 @default.
• W3095043345 hasConcept C2778461978 @default.
• W3095043345 hasConcept C2778822529 @default.
• W3095043345 hasConcept C2778850193 @default.
• W3095043345 hasConcept C2779675984 @default.
• W3095043345 hasConcept C2780007613 @default.
• W3095043345 hasConcept C2780235182 @default.
• W3095043345 hasConcept C2780240888 @default.
• W3095043345 hasConcept C2780817109 @default.
• W3095043345 hasConcept C31760486 @default.
• W3095043345 hasConcept C38652104 @default.
• W3095043345 hasConcept C41008148 @default.
• W3095043345 hasConcept C535046627 @default.
• W3095043345 hasConcept C55493867 @default.
• W3095043345 hasConcept C71924100 @default.
• W3095043345 hasConcept C87355193 @default.
• W3095043345 hasConcept C90924648 @default.
• W3095043345 hasConcept C9583187 @default.
• W3095043345 hasConceptScore W3095043345C104317684 @default.
• W3095043345 hasConceptScore W3095043345C121332964 @default.
• W3095043345 hasConceptScore W3095043345C126322002 @default.
• W3095043345 hasConceptScore W3095043345C142424586 @default.
• W3095043345 hasConceptScore W3095043345C143998085 @default.
• W3095043345 hasConceptScore W3095043345C150194340 @default.
• W3095043345 hasConceptScore W3095043345C185592680 @default.
• W3095043345 hasConceptScore W3095043345C190727270 @default.
• W3095043345 hasConceptScore W3095043345C197934379 @default.
• W3095043345 hasConceptScore W3095043345C203092338 @default.
• W3095043345 hasConceptScore W3095043345C2776063141 @default.
• W3095043345 hasConceptScore W3095043345C2776239401 @default.
• W3095043345 hasConceptScore W3095043345C2776364478 @default.
• W3095043345 hasConceptScore W3095043345C2776694085 @default.
• W3095043345 hasConceptScore W3095043345C2777063308 @default.
• W3095043345 hasConceptScore W3095043345C2777928532 @default.
• W3095043345 hasConceptScore W3095043345C2777938653 @default.
• W3095043345 hasConceptScore W3095043345C2778375690 @default.
• W3095043345 hasConceptScore W3095043345C2778461978 @default.
• W3095043345 hasConceptScore W3095043345C2778822529 @default.
• W3095043345 hasConceptScore W3095043345C2778850193 @default.
• W3095043345 hasConceptScore W3095043345C2779675984 @default.
• W3095043345 hasConceptScore W3095043345C2780007613 @default.
• W3095043345 hasConceptScore W3095043345C2780235182 @default.
• W3095043345 hasConceptScore W3095043345C2780240888 @default.
• W3095043345 hasConceptScore W3095043345C2780817109 @default.
• W3095043345 hasConceptScore W3095043345C31760486 @default.
• W3095043345 hasConceptScore W3095043345C38652104 @default.
• W3095043345 hasConceptScore W3095043345C41008148 @default.
• W3095043345 hasConceptScore W3095043345C535046627 @default.
• W3095043345 hasConceptScore W3095043345C55493867 @default.

• next